Ann: Letter to Shareholders, Notice of Meeting & Proxy Form, page-40

I don't say too much here because as Dirty Harry says, "A man's got to know his limitations" but I remember from years ago, maybe earlyish 2020 that if all else failed getting Zantrene approved as a chemotherapeutic for AML only would be worth $12 per share. Now the SOI haven't increased that much since then so that has always been the minimum figure I would consider based on the company's prospects at the time. Obviously I would be guided by the board. Hopefully some others remember this maybe other long termers like Titans, II, John, LT or Eddy to name a few. I'm still very confident that we'll get a transaction and for me the opportunity cost is not being in RAC when that time comes. My dodgy memory and opinion only. Have a great 2023 everyone.